Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. The Company also offers expert consulting services related to fundamental chelation chemistry and bioconjugation. Its molecular imaging platform technology is adaptable to a broad range of radionuclides such as copper 64, gallium 68 and zirconium 89 for positron emission tomography (PET) and gadolinium and other lanthanide ions for optical and magnetic resonance imaging (MRI). The Company's products include an extensive line of bifunctional ligands designed specifically for bio-targeting in combination with monoclonal antibodies and peptide fragments. Macrocyclics introduced its cGMP manufacturing services in 2005. Its quality system is designed specifically for the manufacture of APIs to be used in clinical trials.